The purpose of this study is to evaluate the efficacy and safety of albuvirtide combined with
lopinavir-ritonavir (LPV/r) in HIV-1-infected patients who failed first-line antiretroviral
therapy (ART).
Phase:
Phase 3
Details
Lead Sponsor:
Frontier Biotechnologies Co., Ltd. Frontier Biotechnologies Inc.